Progress in the development of early-onset antidepressants

Chinese Pharmacological Bulletin

Volumn 24, Issue 12, 2008, Pages 1558-1561

  Xue, Rui ^a,b   Zhang, You Zhi ^a   Zou, Li Bo ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 HT1A antagonist; 5 HT2A antagonist; Antidepressant; Dual triple reuptake inhibitors; Onset of action; 2 antagonist

Indexed keywords

2 [[(7 FLUORO 4 INDANYL)OXY]METHYL]MORPHOLINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; FLUOXETINE; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; RISPERIDONE; ROBALZOTAN; SEROTONIN 1A ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VILAZODONE; VOLINANSERIN;

ARTICLE; DEPRESSION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; MOOD DISORDER; NONHUMAN;

EID: 60749115406     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. World Health Organization: Annual report. Metal health: new hopes,new perspectives[R]. Geneva, Switzerland: WHO, 2001.
2. Schildkraut J J. The catecholamine hypothesis of affective disorders: a review of supporting evidence[J]. Am J Psychiatry, 1965, 122(5):509-22.
3. Stockmeier C A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter [J]. J Psychiatry Res, 2003, 37 (5):357-73.
4. Piñeyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action [J]. Pharmacol Rev, 1999, 51 (3):533-91.
5. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT [J]. Br J Pharmacol, 1995 , 115(6):1064-70.
6. Artigas F, Celada P, Laruelle M, Adell A. How does pindolol improve antidepressant action [J]? Trends Pharmacol Sci, 2001, 22 (5):224-8.
7. Blier P. The pharmacology of putative early-onset antidepressant strategies [J]. Eur Neuropsychopharmacol, 2003, 13 (2):57-66.
8. 11C] WAY-100635 and position emission tomography in humans [J]. Neuropsychopharmacology, 2000, 24 (3):209-29.
9. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants [J]. Science, 2003, 301 (5634):805-9.
10. Zhang L M, Li Y F, Liu Y Q, et al. Effect of quercetin 3-O-apiosyl (1→2)-rhamnosyl (1→6)-glucoside on the proliferation of neural progenitor cells from neonatal rat hippocampus [J]. Chin Pharmacol Bull, 2006,22 (2):168-71.
11. 1A agonists in the treatment of depression [J]? Biol Psychiatry, 2003,53 (3):193-203.
12. Maeda J, Morio Y, Oohashi Y, et al. Wf-516, a novel antidepressant with dual serotonergic activity: I, Receptorial and pharmacological profiles in comparison with reference antidepressants[J]. Eur Neuropsychopharmacol, 2006, 116: S333.
13. Starr K R, Price G W, Watson J M,et al. SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test [J]. Neuropsychopharmacology, 2007,32 (10): 2163-72.
14. Blier P, Haddieri N, Szabo S T, Dong J M. Enhancement of serotoninergic function-a sometimes insufficient cause of antidepressant action [J]. Hum Psychopharmacol,2001,16 (1):23-7.
15. 2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine [J]. Neuropsychopharmacology, 2005,30(12):2205-15.
16. Hirose S, Ashby C R Jr. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy [J]. J Clin Psychiatry, 2002,63 (8):733-6.
17. 2A receptor antagonism on the firing activity of norepinephrine neurons [J]. J Pharmacol Exp Ther,2002,302 (3):983-91.
18. 2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides[J]. J Neurochem, 1999, 72(1):282-91.
19. Anand A, Charney D S. Norepinephrine dysfunction in depression [J]. J Clin Psychiatry,2000,61 (suppl 10):16-24.
20. Thase M E, Entsuah A R, Rudolph R L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors [J]. Br J Psychiatry,2001,178:234-41.
21. Adell A, Castro E, Celada P, et al. Strategies for producing faster acting antidepressants[J]. Drug Discov Today,2005, 10 (8):578-85.
22. Lavretsky H, Kim M D, Kumar A, Reynolds C F 3rd. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial [J]. J Clin Psychiatry, 2003,64 (12):1410-4.
23. Lam R W, Hossie H, Solomons K, Yatham L H. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression [J]. J Clin Psychiatry, 2004,65 (3):337-40.
24. Mathew S J, Manji H K, Charney D S. Novel drugs and therapeutic targets for severe mood disorders [J]. Neuropsychopharmacology, 2008:1-13.
25. Lou J S, Li C Y. Progress of receptors mechanism on depression [J]. Chin Pharmacol Bull, 2006,22 (10):1157-60.